Overview
Portfolio
More
H
Cincinnati, United States
Seed to early growth equity fund focusing on consumer products and devices, with a geographic focus on the United States and Canada, particularly New York and San Francisco.
Portfolio
15+
Employees
10+
Founded
2017
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
CanadaUnited States
Sources
H
Seed to early growth equity fund focusing on consumer products and devices, with a geographic focus on the United States and Canada, particularly New York and San Francisco.
Portfolio
15+
Employees
10+
Founded
2017
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
CanadaUnited States
Sources
Showing 3 of 3 matched portfolio companies
Mad Rabbit provides a clinically formulated line of tattoo‑care products—including moisturizers, balms, soothing gels, numbing creams, sunscreens, and cleansers—designed to preserve ink brightness, soothe irritation, and protect skin from UV and harsh chemicals. All formulations are free of parabens, sulfates, phthalates, and artificial fragrances, offering both immediate post‑procedure care and long‑term maintenance for vibrant, healthy tattoos.
Funding: $10.0M
Rough estimate of the amount of funding raised
Funding: $10.0M
Rough estimate of the amount of funding raised
Mother Science develops skincare products utilizing Malassezin, a patented molecule that is ten times more effective than vitamin C as an antioxidant. Their formulations specifically target dark spots, fine lines, and uneven skin tone, delivering measurable improvements in skin brightness and texture within four weeks of use.
Funding: $9.7M
Rough estimate of the amount of funding raised
Funding: $9.7M
Rough estimate of the amount of funding raised
The startup offers subscription-based personalized healthcare that integrates chronic disease diagnosis and management through telemedicine consultations, health coaching, lab testing, and specialist referrals. This approach enables patients to receive tailored treatment that targets the underlying causes of their chronic conditions rather than merely addressing symptoms.
Funding: $143.8M
Rough estimate of the amount of funding raised
Funding: $143.8M
Rough estimate of the amount of funding raised
Showing 12 of 12 unmatched portfolio companies